Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Fineline Cube Feb 10, 2026
Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Fineline Cube Feb 10, 2026
Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Fineline Cube Feb 10, 2026
Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026
Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Deals

Shanghai Pharma and Cutia Therapeutic Collaborate on Codon Biopharma’s Innovative Drug Distribution

Fineline Cube Jul 22, 2025

China’s Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced the signing of...

Company Drug

Bio-Thera’s BAT4406F Gets NMPA Nod for MCD and FSGS Clinical Trials

Fineline Cube Jul 22, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that its investigational drug, BAT4406F injection, has received approval...

Company Drug

Huadong Medicine Receives NMPA Approval for HDM2012 Clinical Trials in Advanced Solid Tumors

Fineline Cube Jul 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Deals Medical Device

Optoseeker Biotech and BioMap Collaborate to Accelerate Antibody Therapeutics Development

Fineline Cube Jul 21, 2025

Optoseeker Biotech, a leader in advanced life science instrumentation, and BioMap, a pioneer in life...

Company Medical Device

Wondfo Biotech’s MSI Detection Kit Granted NMPA Marketing Clearance

Fineline Cube Jul 21, 2025

Guangzhou-based Wondfo Biotech (SHE: 300482) announced that the National Medical Products Administration (NMPA) has granted...

Company Medical Device

Zhongke Yian Receives NMPA Approval for Innovative Sirolimus-Eluting Coronary Stent

Fineline Cube Jul 21, 2025

ZhongKe Yian Medical Technology (Beijing) Co., Ltd. has secured approval from China’s National Medical Products...

Company Drug

NMPA Approves World’s First Plant-Based Human Albumin for Liver Cirrhosis Treatment

Fineline Cube Jul 21, 2025

China’s National Medical Products Administration (NMPA) has approved the world’s first plant-based human albumin, a...

Company Medical Device

KANTE Biotech’s Yilijia Wins NMPA Category III License for Pancreatic Cancer Early Detection

Fineline Cube Jul 21, 2025

KANTE (Shenzhen) Biotechnology Co., Ltd (“Kante-bio”) announced that it has received a Category III medical...

Company

WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings

Fineline Cube Jul 21, 2025

WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities...

Company Drug

Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment

Fineline Cube Jul 21, 2025

Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike...

Policy / Regulatory

CDE Seeks Feedback on 96th Batch of Chemical Generic Drug Reference Standards

Fineline Cube Jul 21, 2025

China’s Center for Drug Evaluation (CDE) is currently seeking public feedback on the 96th batch...

Company Drug

Novo Nordisk’s Ozempic Approved for Kidney Protection in China, Pioneering Glycemic and Renal Control

Fineline Cube Jul 21, 2025

The National Medical Products Administration has granted approval to Novo Nordisk’s (NYSE: NVO) once-weekly semaglutide...

Company Deals

Shanghai Wankexin Biotech to Acquire Stake in Chengdu Kanghua Biological for RMB 1.851 Billion

Fineline Cube Jul 21, 2025

Shanghai Wankexin Biotechnology Partnership Enterprise (Limited Partnership) (“Wankexin Biotech”), a subsidiary of the Shanghai Biomedicine...

Policy / Regulatory

Hebei Implements Separate Payment for 57 Negotiated Drugs Starting August 1, 2025

Fineline Cube Jul 21, 2025

The Hebei provincial healthcare security administration has issued the “Notice on Improving the Separate Payment...

Company Deals

Bayer and JD Health Collaborate on Dulcolax-Lactulose to Expand China’s Digestive-Health Market

Fineline Cube Jul 21, 2025

Bayer (ETR: BAYN) and JD Health (HKG: 6618) have launched Dulcolax-branded lactulose in a pioneering...

Company Drug

Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension

Fineline Cube Jul 21, 2025

US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500...

Company Deals

VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies

Fineline Cube Jul 21, 2025

VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million...

Company Drug

Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029

Fineline Cube Jul 18, 2025

China-based Youcare Pharma (SHA: 688658) announced that its subsidiary Youcare InnoTech and partner Hangzhou Tianlong...

Company Drug

GSK’s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma

Fineline Cube Jul 18, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the US Food and Drug Administration (FDA) Oncologic...

Company Deals

Robo Medical Secures Tens of Millions in Funding for EndoFaster and EndoDreams Development

Fineline Cube Jul 18, 2025

China-based Robo Medical Technology Co. has closed a strategic funding round amounting to “tens of...

Posts pagination

1 … 81 82 83 … 622

Recent updates

  • Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal
  • Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million
  • Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal
  • Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million
  • Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.